Gallium citrate - Aridis Pharmaceuticals

Drug Profile

Gallium citrate - Aridis Pharmaceuticals

Alternative Names: Panaecin

Latest Information Update: 12 Jan 2017

Price : $50

At a glance

  • Originator Aridis Pharmaceuticals
  • Class Antibacterials; Citrates; Contrast media; Heavy metals; Radioisotopes; Radiopharmaceutical diagnostics; Radiopharmaceuticals; Small molecules
  • Mechanism of Action DNA synthesis inhibitors; Multienzyme complex inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Cystic fibrosis-associated respiratory tract infections

Most Recent Events

  • 10 Jan 2017 Aridis Pharmaceuticals plans a phase IIa trial for cystic fibrosis
  • 23 May 2013 Gallium citrate is still in phase I trials for Cystic fibrosis-associated respiratory tract infections in USA
  • 04 Nov 2011 Phase-I trials in Cystic fibrosis-associated respiratory tract infections in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top